Zevra Therapeutics will present at the J.P. Morgan Healthcare Conference on January 15, 2026, with one-on-one meetings available.
Quiver AI Summary
Zevra Therapeutics, Inc. announced its participation in the J.P. Morgan 44th Annual Healthcare Conference, where members of its executive leadership team will present on January 15, 2026, at 9:45 a.m. PT in San Francisco. The company, focused on developing therapies for rare diseases, highlights its success with its lead product for Niemann-Pick disease type C and aims to expand access through geographic opportunities and a pipeline of rare disease programs. Management will also be available for one-on-one meetings with conference attendees. Investors can access a live webcast on Zevra's website. The press release includes a caution regarding forward-looking statements, outlining risks and uncertainties that could affect future outcomes.
Potential Positives
- Zevra Therapeutics is participating in the prestigious J.P. Morgan 44th Annual Healthcare Conference, highlighting its relevance and visibility in the healthcare sector.
- The availability of one-on-one meetings with the executive leadership at the conference could foster valuable connections with potential investors and partners.
- Zevra's lead product is already marketed in the U.S. for a rare disease, demonstrating the company's capability in commercializing therapeutics and building a solid corporate foundation.
- The company's emphasis on geographic expansion and a diverse pipeline of rare disease programs signifies growth potential and commitment to addressing unmet medical needs.
Potential Negatives
- Potential concerns may arise from the company's reliance on forward-looking statements, which are subject to numerous uncertainties and risks that could materially affect actual results.
- The press release mentions that the company has a pipeline of rare disease programs but does not provide additional details, which may lead to investor skepticism regarding future growth and developments.
- The reference to “long-term value” for patients, partners, and shareholders may signal that immediate results may not be forthcoming, possibly indicating a longer investment horizon is needed.
FAQ
When is Zevra Therapeutics presenting at the J.P. Morgan Healthcare Conference?
Zevra Therapeutics will present on January 15, 2026, at 9:45 a.m. PT.
Where can I find the live webcast for Zevra's presentation?
The live webcast will be available on the “Events & Presentations” page of Zevra’s Investor Relations website.
What is Zevra Therapeutics focused on?
Zevra Therapeutics focuses on providing therapies for individuals living with rare diseases.
What condition does Zevra’s lead product target?
Zevra’s lead product is marketed for Niemann-Pick disease type C, a rare neurodegenerative disorder.
How can I contact Zevra for investor relations?
You can contact Nichol Ochsner at +1 (732) 754-2545 or via email at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ZVRA Insider Trading Activity
$ZVRA insiders have traded $ZVRA stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ZVRA stock by insiders over the last 6 months:
- NEIL F. MCFARLANE (President and CEO) sold 19,500 shares for an estimated $210,908
- ALVIN SHIH purchased 20,000 shares for an estimated $157,800
- JOHN B BODE purchased 5,000 shares for an estimated $45,824
- TAMARA A FAVORITO purchased 3,175 shares for an estimated $24,718
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZVRA Revenue
$ZVRA had revenues of $26.1M in Q3 2025. This is an increase of 605.36% from the same period in the prior year.
You can track ZVRA financials on Quiver Quantitative's ZVRA stock page.
$ZVRA Hedge Fund Activity
We have seen 105 institutional investors add shares of $ZVRA stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP removed 1,958,318 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $18,623,604
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,943,000 shares (-46.6%) from their portfolio in Q3 2025, for an estimated $18,477,930
- ALTIUM CAPITAL MANAGEMENT LLC removed 1,287,333 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $12,242,536
- WOODLINE PARTNERS LP removed 1,139,533 shares (-24.7%) from their portfolio in Q3 2025, for an estimated $10,836,958
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,044,021 shares (+646.5%) to their portfolio in Q3 2025, for an estimated $9,928,639
- MARSHALL WACE, LLP added 912,299 shares (+inf%) to their portfolio in Q3 2025, for an estimated $8,675,963
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 715,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $6,799,650
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ZVRA Analyst Ratings
Wall Street analysts have issued reports on $ZVRA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 11/06/2025
- JMP Securities issued a "Market Outperform" rating on 08/13/2025
To track analyst ratings and price targets for $ZVRA, check out Quiver Quantitative's $ZVRA forecast page.
$ZVRA Price Targets
Multiple analysts have issued price targets for $ZVRA recently. We have seen 3 analysts offer price targets for $ZVRA in the last 6 months, with a median target of $24.0.
Here are some recent targets:
- Kristen Kluska from Cantor Fitzgerald set a target price of $24.0 on 11/06/2025
- Sumant Kulkarni from Canaccord Genuity set a target price of $24.0 on 11/06/2025
- Jason N. Butler from JMP Securities set a target price of $18.0 on 08/13/2025
Full Release
CELEBRATION, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will present at the J.P. Morgan 44 th Annual Healthcare Conference in San Francisco, CA on Thursday, January 15, 2026, at 9:45 a.m. PT.
Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the “ Events & Presentations ” page in the Investor Relations section of Zevra’s website at investors.zevra.com .
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.
For more information, please visit www.zevra.com or follow us on X and LinkedIn .
Caution Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, filed on November 5, 2025, as well as Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
[email protected]
Media Contact
Julie Downs
+1 (508) 246-3230
[email protected]
